Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Mepifiline** is the 1:1 salt of the first-generation antihistamine mepyramine and acefylline, also called theophylline-7-acetic acid. It was developed as an orally administered treatment for respiratory disease, combining histamine H1-receptor antagonism from the mepyramine moiety with xanthine-derived bronchodilator activity. A randomized, double-blind study evaluated oral mepyramine-theophylline-acetate in children aged 2 to 6 years with mild-to-moderate asthmatic crisis; the treated group used less rescue salbutamol than the placebo group. ([pubchem.ncbi.nlm.nih.gov](https://pubchem.ncbi.nlm.nih.gov/compound/Mepifiline))
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on mepifiline.